{"links":{"feed":"https://www.erudio.com/reports/omaha-003-nct06136624/feed.json","html":"https://www.erudio.com/reports/omaha-003-nct06136624","json":"https://www.erudio.com/reports/omaha-003-nct06136624.json","markdown":"https://www.erudio.com/reports/omaha-003-nct06136624.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"omaha-003-nct06136624"}},"request":"https://www.erudio.com/contact?report=omaha-003-nct06136624"},"offer":{"cited_clinicians":3,"cited_commentary_sources":8,"verified_hcp_statements":34,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"omaha-003-nct06136624"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=omaha-003-nct06136624","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/omaha-003-nct06136624","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 34 verified statements · 7 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-14T14:04:10.255596Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: OS in AR LBD Mutation-Negative Participants"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":3,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":5,"title":"AR-LBD resistance, steroid ligands and ctDNA work-up"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":13,"cited_clinicians":3,"cited_clinicians_by_role":{"physician, Medical oncology":2,"physician, Urology":1},"cited_physicians":3,"cited_sources":9,"claims_by_expression_type":{"comparison":2,"interpretation":12,"opinion":2,"primary_context":5,"restatement":9,"uncertainty":1,"unspecified":3},"claims_by_kind":{"protocol_statement":4,"publication_statement":11,"source_observation":19},"clinician_statements":7,"evidence_units":23,"findings":2,"organisational_accounts":1,"people_cited":5,"people_identity_verified":4,"people_total":5,"screened_sources":22,"verified_claims":34},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"publication":1}},"title":"Speakers describe adrenal hormone replacement as essential to the opevesostat strategy"},{"cited_clinicians":2,"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":4},"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":8,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"publication":1}},"title":"One speaker and one X account see a mutation-based rationale for upstream steroid suppression"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers describe adrenal hormone replacement as essential to the opevesostat strategy"},{"id":"section-2","level":2,"title":"One speaker and one X account see a mutation-based rationale for upstream steroid suppression"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"What does CYPIDES activity across AR mutation groups imply for further testing?"},{"id":"section-5","level":3,"title":"What does MK-5684-004 research access imply for OMAHA-003?"},{"id":"section-6","level":3,"title":"One X account sees next-generation trials as an effort to redefine mCRPC sequencing"},{"id":"section-7","level":3,"title":"One treatment-experience reply values OMAHA-003 while anticipating later options"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants"},{"findings":[],"id":"T2","label":"Primary endpoint: OS in AR LBD Mutation-Negative Participants"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-14T14:04:10.255596Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-14T14:15:49Z","record_hash":"e616ddb8f5abe7807a688ff2fe9b0bc85ec895001295b0a5d77ea76043e44964","release_hash":"a099a483e7479ccc88bfeeceb58bbf274830d7703e1ff5cea08b41db4a688c20","report_id":"erudio-nct06136624","run_id":"48461156-04c6-484e-bb47-63404f323c89","schema_version":"5.0","slug":"omaha-003-nct06136624","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For OMAHA-003, a medical oncologist described in the source as involved in the trial considers glucocorticoid and mineralocorticoid supplementation necessary because steroid production is blocked. They and a urologist see a rationale for reducing hormones that can activate mutated AR, but AR-LBD status is not established as a treatment-selection rule. Clinical benefit and comparative safety cannot be judged from these statements.","examples":[],"meta_description":"22 sources screened · 34 verified statements (7 from clinicians verified by NPI or staff page) from 9 sources · 2 findings. Updated Nov 14, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-14T14:15:49Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on efficacy and toxicity of adding mevrometostat to enzalutamide after abiraterone in metastatic castration-resistant prostate cancer.","6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 23 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, organizational relays and repeated posts by one account must not be counted as additional independent clinical assessments.","Coverage centers on the trial identifier and known names. Discussion using unnamed references, different wording or other transcription variants may be missing.","Earlier CYPIDES activity and planned OMAHA-003 methods do not establish OMAHA-003 efficacy, survival benefit or comparative safety.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A separate protocol document was not available from ClinicalTrials.gov; the published design report supplies methodological context rather than a complete protocol.","Regulatory coverage is incomplete, and no exact opevesostat label was identified. No approved indication or regulatory treatment role can be concluded from this report."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":1,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":8,"methods":1},"count":9,"evidence_window":{"end":"2026-10-23","start":"2025-04-30"},"retrieval_snapshot":"2026-11-14T13:21:04.308406Z","timeline":[{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06136624:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06136624:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41732008","quote_policy":"no_derivatives"},{"id":"openfda:413c645e-074d-4276-b39a-d83521077602:20261026","quote_policy":"short_quote_link_out"},{"id":"openfda:b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf:20260728","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7323289995190943746","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2f249c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1763692318853587214:3bf98773-841f-4a52-9550-f045d5df5c29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797268490564280804:4e0223b8-4563-4af7-892c-91a99e8ecf12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797269437759840448:056189a0-fbf8-4590-8596-e78099042c4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797308512143396881:c8bb0627-afdb-4329-bc67-9cf1546a4649","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865097720597262617:4d14779d-b878-42ad-afa0-d56398a51273","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975238932297359536:a8cfbdd0-936b-4d3b-a53b-fcc17cc63a0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978871148818636935:9daff2b5-4ed7-46a8-a2e9-426d1f5bcbe5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991495413720109405:48d52d2e-86a9-4674-a80f-e463b7713226","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027488462538936430:6aa37b57-e323-4818-9828-7fbc79318fb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027798495999001001:38a0179a-b9be-4799-bae0-b5cdfb0fc9d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037575488508481767:7fbb79d6-cee1-40ba-83cc-62fce92a20ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047646819677577492:1cfd6c3f-bc25-44c8-9f8f-732783c2f6c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050511552919257494:927fde40-f73e-4169-8408-570031e2c124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056172008535191908:43396377-52e5-4336-ba99-9e8c6941ab0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056721611944833198:aaf55451-5aa4-4e53-b52f-dd8374362cf7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059452248879694090:d2cffc4c-7b47-4c2c-b4a0-cb64f5b2227d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066853343364870212:01842de9-fbc1-490d-a1eb-fd95d5f1f4c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079174544514813955:ee74a00e-217c-46ba-9db5-30e5a1df6ea3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118644569323733146:c855d6cb-b4ad-4b67-8016-cafdfa0dc78a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DbeYMuV_tdo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-11-06","start":"2024-03-01"},"retrieval_snapshot":"2026-11-14T13:21:04.753227Z","timeline":[{"count":1,"week":"2024-W09"},{"count":3,"week":"2024-W22"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W47"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":4,"publication":15,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":8}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: opevesostat","status":"unmapped"},{"brand_names":["Zytiga"],"label":"abiraterone acetate","slug":"abiraterone-acetate"},{"brand_names":["Xtandi"],"label":"enzalutamide","slug":"enzalutamide"},{"reason":"Unmapped registry intervention: hydrocortisone","status":"unmapped"},{"reason":"Unmapped registry intervention: fludrocortisone acetate","status":"unmapped"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"}],"indications":[{"reason":"Unmapped registry condition: Prostate Cancer Metastatic","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"OMAHA-003","aliases":["OMAHA-003","Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)"],"brief_title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostate Cancer Metastatic"],"display_condition":"mCRPC after NHA and taxane-based chemotherapy","display_interventions":[["opevesostat"]],"enrollment":{"count":1310,"type":"ESTIMATED"},"interventions":[{"name":"Opevesostat","synonyms":["MK-5684"],"type":"DRUG"},{"name":"Abiraterone acetate","synonyms":["ZYTIGA","YONSA"],"type":"DRUG"},{"name":"Enzalutamide","synonyms":["XTANDI"],"type":"DRUG"},{"name":"Hydrocortisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fludrocortisone acetate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06136624","official_title":"A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-11-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-positive participants will be reported for each study arm.","measure":"Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants","timeFrame":"Up to ~54 months"},{"description":"OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-negative participants will be reported for each study arm.","measure":"OS in AR LBD Mutation-Negative Participants","timeFrame":"Up to ~54 months"}],"registered_date":{"date":"2023-11-18","type":"ACTUAL"},"registry_last_updated":"2026-11-13","registry_url":"https://clinicaltrials.gov/study/NCT06136624","short_name":"OMAHA-003","short_name_basis":"registry_acronym","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2023-12-31","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"5684-003","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-504899-25-00","type":"other"},{"domain":"MSD","id":"MK-5684-003","type":"other"},{"domain":"Japan Registry of Clinical Trials (jRCT)","id":"jRCT2031240029","type":"registry"},{"domain":"UTN","id":"U1111-1287-5304","type":"registry"}],"study_type":"INTERVENTIONAL"}}}